Skip to main content
SpringerLink
Log in

Wo steht das künstliche Pankreas in der Diabetestherapie?

What is the current state of the artificial pancreas in diabetes care?

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Das künstliche Pankreas (auch Closed-loop-System genannt) bringt uns dem jahrzehntelangen Traum einer automatisierten Insulindosierung einen Schritt näher. Das System steuert die subkutane Insulinzufuhr mit einem Kontrollalgorithmus entsprechend der Glukosekonzentration. Die Studienlage zeigt, dass damit die Blutzuckerkontrolle und Lebensqualität Betroffener deutlich verbessert werden können. Vollautomatische Closed-loop-Systeme sind jedoch noch nicht erhältlich. Patienten müssen bei der Insulindosierung für Mahlzeiten und Korrekturen zusätzlich aktiv mitwirken. Die folgende Übersichtsarbeit zeigt den aktuellen Entwicklungsstand des künstlichen Pankreas in der Diabetestherapie auf.

Abstract

The artificial pancreas (also referred to as closed-loop system) brings us one step closer to the decade-long dream of automated insulin delivery. The closed-loop system directs subcutaneous insulin delivery corresponding to the glucose concentration using a control algorithm. Evidence shows that closed-loop systems substantially improve glucose control and quality of life; however, fully automated closed-loop systems have not yet been accomplished. Active input from patients is required for mealtime insulin dosing and corrections. This article provides an overview on the current state of development of the artificial pancreas in the treatment of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW et al (2018) IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281

    Article  CAS  Google Scholar 

  2. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986

    Article  CAS  Google Scholar 

  3. Pickup JC, Keen H, Parsons JA, Alberti KG (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1(6107):204–207

    Article  CAS  Google Scholar 

  4. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D et al (2017) Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 167(6):365–374

    Article  Google Scholar 

  5. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S et al (2017) Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317(4):371–378

    Article  CAS  Google Scholar 

  6. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R (2016) Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(16)31535-5

    Article  PubMed  Google Scholar 

  7. Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I et al (2017) REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 40(4):538–545

    Article  Google Scholar 

  8. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31(5):934–939

    Article  Google Scholar 

  9. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. https://doi.org/10.1016/s2213-8587(17)30167-5

    Article  PubMed  Google Scholar 

  10. Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T et al (2018) Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ 361:k1310

    Article  Google Scholar 

  11. Haidar A, Messier V, Legault L, Ladouceur M, Rabasa-Lhoret R (2017) Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial. Diabetes Obes Metab 19(5):713–720

    Article  CAS  Google Scholar 

  12. Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408

    Article  Google Scholar 

  13. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW et al (2019) Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther 21(1):11–19

    Article  CAS  Google Scholar 

  14. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381(18):1707–1717

    Article  CAS  Google Scholar 

  15. Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP et al (2016) Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 375(7):644–654

    Article  CAS  Google Scholar 

  16. Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME et al (2018) Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. https://doi.org/10.1056/nejmoa1805233

    Article  PubMed  Google Scholar 

  17. Melmer A, Züger T, Lewis DM, Leibrand S, Stettler C, Laimer M (2019) Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS). Diabetes Obes Metab 21(10):2333–2337

    Article  CAS  Google Scholar 

  18. https://openaps.org. Zugegriffen: 11. Nov. 2019

  19. https://androidaps.readthedocs.io/en/latest/CROWDIN/de/. Zugegriffen: 11. Nov. 2019

  20. https://wirwartennicht.info/index.php/loop. Zugegriffen: 11. Nov. 2019

  21. Taleb N, Emami A, Suppere C, Messier V, Legault L, Ladouceur M et al (2016) Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia. https://doi.org/10.1007/s00125-016-4107-0

    Article  PubMed  Google Scholar 

  22. Castle JR, El Youssef J, Wilson LM, Reddy R, Resalat N, Branigan D et al (2018) Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care 41(7):1471–1477

    Article  CAS  Google Scholar 

  23. Boughton CK, Hartnell S, Allen JM, Hovorka R (2019) The importance of prandial insulin bolus timing with hybrid closed-loop systems. Diabet Med. https://doi.org/10.1111/dme.14116

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bally L, Herzig D, Ruan Y, Wilinska ME, Semmo M, Vogt A et al (2019) Short-term fully closed-loop insulin delivery using faster insulin aspart compared to standard insulin aspart in type 2 diabetes. Diabetes Obes Metab. https://doi.org/10.1111/dom.13861

    Article  PubMed  Google Scholar 

  25. Dovc K, Piona C, Yeşiltepe Mutlu G, Bratina N, Jenko Bizjan B, Lepej D et al (2019) Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial. Diabetes Care. https://doi.org/10.2337/dc19-0895

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Praxiszentrum am Bahnhof Bern, Hirslanden, Schweiz

    M. Dimou

  2. Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin und Metabolismus, Inselspital Bern, Freiburgstrasse, 3010, Bern, Schweiz

    M. Dimou,  M. Laimer,  C. Stettler &  L. Bally

Authors
  1. M. Dimou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Laimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Stettler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Bally
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bally.

Ethics declarations

Interessenkonflikt

M. Dimou, M. Laimer, C. Stettler und L. Bally geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

M. Wehling, Mannheim

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dimou, M., Laimer, M., Stettler, C. et al. Wo steht das künstliche Pankreas in der Diabetestherapie?. Internist 61, 102–109 (2020). https://doi.org/10.1007/s00108-019-00713-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-00713-y

Schlüsselwörter

Keywords

Search

Navigation